AR024476A1 - Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. - Google Patents
Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen.Info
- Publication number
- AR024476A1 AR024476A1 ARP000103183A ARP000103183A AR024476A1 AR 024476 A1 AR024476 A1 AR 024476A1 AR P000103183 A ARP000103183 A AR P000103183A AR P000103183 A ARP000103183 A AR P000103183A AR 024476 A1 AR024476 A1 AR 024476A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- treatment
- benzacepin
- acetic acid
- acid derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de derivados de ácidos benzacepin-N-acético, que en posicion alfa con relacion al átomo de nitrogeno contienen un grupo oxo y en posicion 3 estánsustituidos con un radical 1-(carboxialquil)-ciclopentil-carbonil-amino, y sus sales y ésteres biolábiles, para la profilaxis y/o tratamiento de lesionescardíacas causadas por dosis cardiotoxicas de fármacos o productos químicos, en mamíferos superiores y particularmente seres humanos. En particular,comprende la profilaxis y/o tratamiento de lesiones cardíacas, particularmente del miocardio, que pueden producirse en el marco de una quimioterapiacitostática. Además se describe el uso de dichos derivados de ácido benzacepin-N-acético para el tratamiento adyuvante en el marco de terapias en que seutilizan medicamentos con efectos secundarios oxidativo-toxicos. También se describe la preparacion de medicamentos adecuados para esta profilaxis y/otratamiento adyuvante.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19932555A DE19932555A1 (de) | 1999-07-13 | 1999-07-13 | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
Publications (1)
Publication Number | Publication Date |
---|---|
AR024476A1 true AR024476A1 (es) | 2002-10-02 |
Family
ID=7914519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000103183A AR024476A1 (es) | 1999-07-13 | 2000-06-23 | Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. |
Country Status (28)
Country | Link |
---|---|
US (1) | US6906059B2 (es) |
EP (1) | EP1200095B1 (es) |
JP (1) | JP4824235B2 (es) |
KR (1) | KR100738940B1 (es) |
CN (1) | CN1267099C (es) |
AR (1) | AR024476A1 (es) |
AT (1) | ATE306926T1 (es) |
AU (1) | AU782733B2 (es) |
BR (1) | BR0012442A (es) |
CA (1) | CA2377904C (es) |
CZ (1) | CZ299070B6 (es) |
DE (2) | DE19932555A1 (es) |
DK (1) | DK1200095T3 (es) |
ES (1) | ES2246874T3 (es) |
HK (1) | HK1049116B (es) |
HU (1) | HUP0202424A3 (es) |
IL (2) | IL147604A0 (es) |
MX (1) | MXPA02000411A (es) |
NO (1) | NO329558B1 (es) |
NZ (1) | NZ517130A (es) |
PL (1) | PL198723B1 (es) |
RU (1) | RU2268727C2 (es) |
SK (1) | SK286020B6 (es) |
TR (1) | TR200200053T2 (es) |
TW (1) | TWI280880B (es) |
UA (1) | UA73134C2 (es) |
WO (1) | WO2001003699A1 (es) |
ZA (1) | ZA200200265B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
CZ20033183A3 (cs) * | 2001-05-18 | 2004-07-14 | Solvay Pharmaceuticals Gmbh | Použití sloučenin s kombinovanou inhibiční aktivitou NEP/ MP v přípravě léčiv |
DE60234952D1 (de) * | 2001-09-10 | 2010-02-11 | Tibotec Pharm Ltd | VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL |
RU2303041C2 (ru) * | 2002-01-16 | 2007-07-20 | Солвей Фармасьютикалс Б.В. | Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений |
AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
AR046454A1 (es) | 2003-11-18 | 2005-12-07 | Solvay Pharm Gmbh | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica |
US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
CA2590278A1 (en) | 2004-12-15 | 2006-06-22 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
NZ594178A (en) * | 2006-02-27 | 2013-02-22 | Targeted Molecular Diagnostics Llc | An ex vivo method of predicting toxicity to tyrosine kinase inhibitors |
WO2007102171A2 (en) * | 2006-03-07 | 2007-09-13 | Panacea Biotec Ltd | Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition |
US20070292503A1 (en) * | 2006-06-16 | 2007-12-20 | Gorissen Henricus R | Oral pharmaceutical composition of poorly water-soluble active substance |
US20070299054A1 (en) * | 2006-06-22 | 2007-12-27 | Rajesh Jain | Oral pharmaceutical composition of a poorly water-soluble active agent |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
AU1146099A (en) * | 1997-09-18 | 1999-04-05 | Janssen Pharmaceutica N.V. | Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents |
DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
-
1999
- 1999-07-13 DE DE19932555A patent/DE19932555A1/de not_active Withdrawn
-
2000
- 2000-06-23 AR ARP000103183A patent/AR024476A1/es unknown
- 2000-07-05 TW TW089113263A patent/TWI280880B/zh active
- 2000-07-10 DK DK00947960T patent/DK1200095T3/da active
- 2000-07-10 PL PL353012A patent/PL198723B1/pl not_active IP Right Cessation
- 2000-07-10 AT AT00947960T patent/ATE306926T1/de active
- 2000-07-10 MX MXPA02000411A patent/MXPA02000411A/es active IP Right Grant
- 2000-07-10 TR TR2002/00053T patent/TR200200053T2/xx unknown
- 2000-07-10 NZ NZ517130A patent/NZ517130A/en not_active IP Right Cessation
- 2000-07-10 WO PCT/EP2000/006525 patent/WO2001003699A1/de active IP Right Grant
- 2000-07-10 CA CA002377904A patent/CA2377904C/en not_active Expired - Fee Related
- 2000-07-10 KR KR1020027000361A patent/KR100738940B1/ko not_active IP Right Cessation
- 2000-07-10 RU RU2002102709/15A patent/RU2268727C2/ru not_active IP Right Cessation
- 2000-07-10 CN CNB008102015A patent/CN1267099C/zh not_active Expired - Fee Related
- 2000-07-10 BR BR0012442-7A patent/BR0012442A/pt not_active Application Discontinuation
- 2000-07-10 HU HU0202424A patent/HUP0202424A3/hu not_active Application Discontinuation
- 2000-07-10 ES ES00947960T patent/ES2246874T3/es not_active Expired - Lifetime
- 2000-07-10 EP EP00947960A patent/EP1200095B1/de not_active Expired - Lifetime
- 2000-07-10 JP JP2001508979A patent/JP4824235B2/ja not_active Expired - Fee Related
- 2000-07-10 CZ CZ20020052A patent/CZ299070B6/cs not_active IP Right Cessation
- 2000-07-10 SK SK14-2002A patent/SK286020B6/sk not_active IP Right Cessation
- 2000-07-10 AU AU61572/00A patent/AU782733B2/en not_active Ceased
- 2000-07-10 IL IL14760400A patent/IL147604A0/xx active IP Right Grant
- 2000-07-10 DE DE50011388T patent/DE50011388D1/de not_active Expired - Lifetime
- 2000-10-07 UA UA2002021058A patent/UA73134C2/uk unknown
-
2002
- 2002-01-11 NO NO20020132A patent/NO329558B1/no not_active IP Right Cessation
- 2002-01-11 ZA ZA200200265A patent/ZA200200265B/xx unknown
- 2002-01-13 IL IL147604A patent/IL147604A/en not_active IP Right Cessation
- 2002-01-14 US US10/043,268 patent/US6906059B2/en not_active Expired - Fee Related
-
2003
- 2003-02-18 HK HK03101159.2A patent/HK1049116B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR024476A1 (es) | Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. | |
AR008878A1 (es) | Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento. | |
AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
ES2054860T5 (es) | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. | |
AR007640A1 (es) | DERIVADOS DE FENILALANINA, PROCEDIMIENTO PARA PREPARARLOS, PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN Y EMPLEO DE LOS MISMOS PARA PREPARAR UNMEDICAMENTO QUE ACTUA COMO INHIBIDOR DE LA INTEGRINA ALFA(v) | |
ES2152222T3 (es) | Sulfonamidas, su preparacion y su uso como medicamento e intermedio. | |
UY38880A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
ES2115725T3 (es) | Hidrocloruro de triazoliltiometiltiocefalosporina, su hidrato cristalino y la preparacion de este. | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
ES2147294T3 (es) | Compuestos terapeuticos. | |
AR004108A1 (es) | Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas | |
AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
AR010894A1 (es) | Aminoacidos aromaticos biciclicos, un procedimiento para prepararlos, preparaciones farmaceuticas que lo contienen y el empleo de los mismos parapreparar un medicamento que actua como inhibidor de la integrina. | |
AR039633A2 (es) | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
ES2045182T3 (es) | Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen. | |
UY26371A1 (es) | Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen | |
AR013864A1 (es) | COMPOSICIONES FARMACEUTICAS PARA LA PREVENCIoN PRIMARIA DEL CANCER DE PECHO EN UNA MUJER POST MENOPÁUSICA Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO | |
ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. | |
AR002957A1 (es) | Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen. | |
ES2056947T3 (es) | Productos opticamente activos de derivados de 20,21-dinoreburnamenina, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
ES2177103T3 (es) | Terapia de combinacion para el tratamiento del sida. | |
PE20050307A1 (es) | 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden | |
ES2144844T3 (es) | Derivados ureido biologicamente activos utiles en el tratamiento de la esclerosis en placas. | |
ES2056849T3 (es) | Heteroalquilen-quinolinaminas condensadas, un procedimiento y productos intermedios para su preparacion y su uso como medicamentos. | |
AR126702A1 (es) | Compuestos fosfolípidos y métodos de preparación y uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |